Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.
Authors
Kerr, K MBubendorf, L
Edelman, M J
Marchetti, A
Mok, T
Novello, S
O'Byrne, K
Stahel, R
Peters, S
Felip, E
Faivre-Finn, Corinne
Affiliation
Department of Pathology, Aberdeen Royal Infirmary and Aberdeen University Medical School, AberdeenIssue Date
2014-09
Metadata
Show full item recordAbstract
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.Citation
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. 2014, 25 (9):1681-90 Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdu145PubMed ID
24718890Type
ArticleLanguage
enISSN
1569-8041ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdu145